Flinton Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Flinton Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$193K	Sell	5,280 -48	-0.9%	-$1.9K	0.01%	677
2019 Q2	$248K	Sell	5,328 -1,392	-21%	-$65.4K	0.01%	644
2019 Q1	$270K	Buy	6,720 +208	+3%	+$9.33K	0.01%	617
2018 Q4	$299K	Sell	6,512 -1,328	-17%	-$64K	0.01%	561
2018 Q3	$348K	Buy	7,840 +6,800	+654%	+$312K	0.01%	598
2018 Q2	$41K	Sell	1,040 -9,056	-90%	-$458K	﹤0.01%	818
2018 Q1	$730K	Buy	10,096 +7,648	+312%	+$562K	0.02%	340
2017 Q4	$161K	Sell	2,448 -1,776	-42%	-$95.6K	0.01%	696
2017 Q3	$212K	Sell	4,224 -512	-11%	-$24.7K	0.01%	605
2017 Q2	$219K	Sell	4,736 -1,600	-25%	-$58.8K	0.01%	558
2017 Q1	$224K	Hold	6,336	–	–	0.01%	476
2016 Q4	$79K	Buy	+6,336	New	+$75.4K	﹤0.01%	644

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Flinton Capital Management's ESPR Position: Q3 2019 in Review

Flinton Capital Management reduced its Esperion Therapeutics (ESPR) stake by 0.9% in Q3 2019, selling an estimated $1.9K and leaving 5,280 shares worth $193K. The position accounts for 0.01% of the portfolio, ranked #677.

Flinton Capital Management first reported a position in ESPR in Q4 2016 and has held it in 12 quarters since. The position peaked at $730K in Q1 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Flinton Capital Management held 5,280 shares of Esperion Therapeutics worth $193K as of Q3 2019.
Flinton Capital Management sold 48 Esperion Therapeutics shares in Q3 2019, an estimated $1.9K.
Esperion Therapeutics made up 0.01% of Flinton Capital Management's portfolio in Q3 2019, its #677 holding.
Flinton Capital Management first reported a position in Esperion Therapeutics in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's Esperion Therapeutics position peaked at $730K in Q1 2018.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.